Kimball Electronics Q4 Adj. EPS Misses; FY27 Guidance Highlights Growth
Kimball Electronics reported a Q4 adjusted loss of $0.01, missing estimates due to margin pressure despite a modest 2.3% sales decline. The company strengthened its balance sheet, reducing debt to a four-year low via $42.4M in operating cash flow. Guidance for FY27 projects 7-9% sales growth, fueled by organic gains and the Helvoet acquisition.

*this image is generated using AI for illustrative purposes only.
Kimball Electronics (NASDAQ: KE) reported a quarterly adjusted loss of $0.01 per share for the fourth quarter ended June 30, 2026, significantly missing the analyst consensus estimate of $0.39. The result represents a sharp deterioration from the $0.34 per share earnings recorded in the same period last year. Quarterly sales came in at $371.6 million, missing the consensus estimate of $373.4 million by 0.48 percent and reflecting a 2.34 percent decline compared to the prior year.
Despite the earnings miss, the company demonstrated strong operational cash generation and balance sheet improvement. Operating income reached $29.1 million, or 7.8% of net sales, while adjusted operating income margin stood at 4.9%. Cash from operations totaled $42.4 million, marking the tenth consecutive quarter of positive operating cash generation. This cash flow enabled the company to reduce debt to $116.6 million, the lowest level in over four years, while maintaining cash reserves of $88.9 million and borrowing capacity of $322.4 million.
Fiscal 2027 Guidance
Looking ahead, Kimball Electronics provided guidance for fiscal 2027 that highlights a return to top-line growth. The company projects net sales in the range of $1,535 - $1,560 million, representing a 7-9% increase compared to fiscal 2026. This growth is expected to be driven by:
- Organic sales growth of 3-5%, with the Medical vertical increasing in the high single to low double-digit range.
- Approximately $60 million in sales from the recently acquired Helvoet Polymer Technologies.
Management expects adjusted operating income to remain in the range of 4.4-4.7% of net sales. Capital expenditures are projected at $50-60 million. CEO Richard D. Phillips noted that the Medical segment is expected to continue outpacing other verticals, representing more than one-third of total company sales in fiscal 2027, aligning with the objective to balance the portfolio across served markets.
What the Numbers Show
The divergence between the modest revenue decline and the severe earnings miss highlights significant margin pressure or cost inefficiencies during the quarter. While sales contracted by only 2.34 percent year-over-year, earnings per share swung from a profit of $0.34 to a loss of $0.01. This indicates that operating leverage failed to protect profitability as revenues dipped, suggesting fixed costs or specific expenses absorbed the entirety of the operational income that would have otherwise contributed to net profit. Notably, the GAAP net income was $8.5 million, driven largely by a $15.0 million gain on disposal, whereas the adjusted metric excluded this non-recurring item, resulting in the reported loss.
| Metric: | Q4 Current | Q4 Prior Year | YoY Change |
|---|---|---|---|
| Adjusted EPS: | $(0.01) | $0.34 | -102.94% |
| Sales: | $371.6 million | $380.5 million | -2.34% |
| Operating Income: | $29.1 million | $16.5 million | +76.4% |
| Cash from Operations: | $42.4 million | N/A | N/A |
The earnings miss was substantial, with the actual adjusted result falling 102.56 percent below the estimated $0.39 per share. Investors should note that the company not only failed to meet the positive earnings expectation but also reversed its year-ago profitability position entirely on an adjusted basis. However, the strong cash conversion days of 82, the best result in 17 quarters, and the reduction in debt suggest improved working capital efficiency and financial flexibility heading into fiscal 2027.
What specific cost inefficiencies or fixed expenses caused the adjusted EPS to swing from a profit to a loss despite operating income increasing by 76.4% year-over-year?
How will the integration of Helvoet Polymer Technologies impact Kimball Electronics' overall margin profile and operational synergies in fiscal 2027?
Given the guidance for 4.4-4.7% adjusted operating income margins, what strategic initiatives is management implementing to prevent the margin compression seen in Q4?





























